MGX (Metagenomi) Change In Receivables : $1.19 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Change In Receivables?

Metagenomi's change in receivables for the quarter that ended in Dec. 2024 was $-0.67 Mil. It means Metagenomi's Accounts Receivable increased by $0.67 Mil from Sep. 2024 to Dec. 2024 .

Metagenomi's change in receivables for the fiscal year that ended in Dec. 2024 was $1.19 Mil. It means Metagenomi's Accounts Receivable declined by $1.19 Mil from Dec. 2023 to Dec. 2024 .

Metagenomi's Accounts Receivable for the quarter that ended in Dec. 2024 was $1.26 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Metagenomi's Days Sales Outstanding for the three months ended in Dec. 2024 was 11.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Metagenomi's liquidation value for the three months ended in Dec. 2024 was $159.51 Mil.

Metagenomi Change In Receivables Historical Data

The historical data trend for Metagenomi's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Change In Receivables Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-1.27

-1.18

1.19

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial						1.47	0.37	0.43	1.06	-0.67

Metagenomi Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.19 Mil.

Metagenomi (NAS:MGX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Metagenomi's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.257	/	9.614	*	91
=	11.93

2. In Ben Graham's calculation of liquidation value, Metagenomi's accounts receivable are only considered to be worth 75% of book value:

Metagenomi's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	248.307	-	89.742	+	0.75 * 1.257	+	0.5 * 0
=	159.51

Metagenomi Change In Receivables Related Terms

Thank you for viewing the detailed overview of Metagenomi's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, Emeryville, CA, USA, 94608

Website

https://www.metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).